255 related articles for article (PubMed ID: 9083493)
1. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase inhibitors: a structure-activity study.
Levy DE; Lapierre F; Liang W; Ye W; Lange CW; Li X; Grobelny D; Casabonne M; Tyrrell D; Holme K; Nadzan A; Galardy RE
J Med Chem; 1998 Jan; 41(2):199-223. PubMed ID: 9457244
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.
Chapman KT; Kopka IE; Durette PL; Esser CK; Lanza TJ; Izquierdo-Martin M; Niedzwiecki L; Chang B; Harrison RK; Kuo DW
J Med Chem; 1993 Dec; 36(26):4293-301. PubMed ID: 8277511
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.
Jacobsen EJ; Mitchell MA; Hendges SK; Belonga KL; Skaletzky LL; Stelzer LS; Lindberg TJ; Fritzen EL; Schostarez HJ; O'Sullivan TJ; Maggiora LL; Stuchly CW; Laborde AL; Kubicek MF; Poorman RA; Beck JM; Miller HR; Petzold GL; Scott PS; Truesdell SE; Wallace TL; Wilks JW; Fisher C; Goodman LV; Kaytes PS
J Med Chem; 1999 May; 42(9):1525-36. PubMed ID: 10229623
[TBL] [Abstract][Full Text] [Related]
6. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent, achiral matrix metalloproteinase inhibitors.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Rydel T; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1998 Sep; 41(19):3568-71. PubMed ID: 9733482
[No Abstract] [Full Text] [Related]
9. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.
MacPherson LJ; Bayburt EK; Capparelli MP; Carroll BJ; Goldstein R; Justice MR; Zhu L; Hu S; Melton RA; Fryer L; Goldberg RL; Doughty JR; Spirito S; Blancuzzi V; Wilson D; O'Byrne EM; Ganu V; Parker DT
J Med Chem; 1997 Aug; 40(16):2525-32. PubMed ID: 9258358
[TBL] [Abstract][Full Text] [Related]
10. Potent, selective pyrone-based inhibitors of stromelysin-1.
Puerta DT; Mongan J; Tran BL; McCammon JA; Cohen SM
J Am Chem Soc; 2005 Oct; 127(41):14148-9. PubMed ID: 16218585
[TBL] [Abstract][Full Text] [Related]
11. A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
Fray MJ; Dickinson RP; Huggins JP; Occleston NL
J Med Chem; 2003 Jul; 46(16):3514-25. PubMed ID: 12877590
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the stromelysin catalytic domain at 2.0 A resolution: inhibitor-induced conformational changes.
Chen L; Rydel TJ; Gu F; Dunaway CM; Pikul S; Dunham KM; Barnett BL
J Mol Biol; 1999 Oct; 293(3):545-57. PubMed ID: 10543949
[TBL] [Abstract][Full Text] [Related]
13. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
[TBL] [Abstract][Full Text] [Related]
14. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1.
Yang W; Lu W; Lu Y; Zhong M; Sun J; Thomas AE; Wilkinson JM; Fucini RV; Lam M; Randal M; Shi XP; Jacobs JW; McDowell RS; Gordon EM; Ballinger MD
J Med Chem; 2006 Feb; 49(3):839-42. PubMed ID: 16451048
[TBL] [Abstract][Full Text] [Related]
15. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, selective, and orally active carboxylic acid based inhibitors of matrix metalloproteinase-13.
Monovich LG; Tommasi RA; Fujimoto RA; Blancuzzi V; Clark K; Cornell WD; Doti R; Doughty J; Fang J; Farley D; Fitt J; Ganu V; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Parker DT; Melton R; O'Byrne E; Pastor G; Pellas T; Quadros E; Reel N; Roland DM; Sakane Y; Singh H; Skiles J; Somers J; Toscano K; Wigg A; Zhou S; Zhu L; Shieh WC; Xue S; McQuire LW
J Med Chem; 2009 Jun; 52(11):3523-38. PubMed ID: 19422229
[TBL] [Abstract][Full Text] [Related]
17. Structure of recombinant mouse collagenase-3 (MMP-13).
Botos I; Meyer E; Swanson SM; Lemaître V; Eeckhout Y; Meyer EF
J Mol Biol; 1999 Oct; 292(4):837-44. PubMed ID: 10525409
[TBL] [Abstract][Full Text] [Related]
18. Identification of potent and selective MMP-13 inhibitors.
Wu J; Rush TS; Hotchandani R; Du X; Geck M; Collins E; Xu ZB; Skotnicki J; Levin JI; Lovering FE
Bioorg Med Chem Lett; 2005 Sep; 15(18):4105-9. PubMed ID: 16005220
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.
Brown FK; Brown PJ; Bickett DM; Chambers CL; Davies HG; Deaton DN; Drewry D; Foley M; McElroy AB; Gregson M
J Med Chem; 1994 Mar; 37(5):674-88. PubMed ID: 8126708
[TBL] [Abstract][Full Text] [Related]
20. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
